Form 4 for EW Edwards Lifesciences

Accepted 2023-05-15 00:00:00 ET · period of report 2023-05-11 · accession 0001225208-23-005913 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-05-15	2023-05-11	EW	Ullem Scott B.	CFO, CVP	A - Grant	$0.00	+9,450	27.7K	+52%	$0
DM	2023-05-15	2023-05-11	EW	Ullem Scott B.	CFO, CVP	A - Grant	$0.00	+84.7K	11.8K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-11	A	A	9,450	$0.00	27,744	D	—	—	(F1) These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
2	Derivative	Employee Stock Option (Right to Acquire)	2023-05-11	A	A	72,900	$0.00	72,900	D	$88.78 · 2024-05-11 to 2030-05-10	72,900 Common Stock	(F2) These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
3	Derivative	Performance Rights	2023-05-11	A	A	11,825	$0.00	11,825	D	— · 2026-05-11 to —	11,825 Common Stock	(F3) Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.